Evidence map›Paper›PMID 40413654›Full record

ArticleJapanese journal of ophthalmology2025

Clinical presentation and prognostic factors of eyelid sebaceous carcinoma.

Yukiko Aihara, Masachika Ikegami, Yoshiyuki Suehara, Takane Watanabe, Seiichi Yoshimoto, Taisuke Mori, Hiroyuki Mano, Shinji Kohsaka, Shigenobu Suzuki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yukiko AiharaDepartment of Ophthalmic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Masachika IkegamiDivision of Cellular Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yoshiyuki SueharaDivision of Cellular Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takane WatanabeDepartment of Head and Neck Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Seiichi YoshimotoDepartment of Head and Neck Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Taisuke MoriDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shinji KohsakaDivision of Cellular Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shigenobu SuzukiDepartment of Ophthalmic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. sgsuzuki@ncc.go.jp.ORCID http://orcid.org/0000-0002-8311-2045

Funding

Fusion Oriented REsearch for disruptive Science and Technology #JPMJFR200Mthe Japan Society for the Promotion of Science KAKENHI #22 K15571the Japan Society for the Promotion of Science KAKENHI #24K18565
6 · The paper itself

Abstract

purposeTo clarify the demographics, clinical features, outcomes, and prognostic factors of Japanese patients with eyelid sebaceous carcinoma. STUDY

designRetrospective study.

methodsFifty-two patients with eyelid sebaceous carcinoma diagnosed histopathologically at the National Cancer Center Hospital in Japan between 2013 and 2023 were reviewed and their outcomes were examined.

resultsThere were 21 men and 31 women. The median age at diagnosis was 73 (range 39-95) years old. The tumor was located in the upper eyelid in 33 patients (63%), in the lower eyelid in 16 patients (31%), and in both eyelids in 3 patients (6%). The initial curative treatment included surgical resection with or without eyelid reconstruction in 41 cases (79%), orbital exenteration in 4 cases (8%), and radiation therapy in 7 cases (13%). Two- and five-year adjusted survival rates were 97.4% and 93.7%, respectively. Local recurrence occurred in 15 cases (29%). Lymph node metastasis was confirmed in 13 cases (27%), distant metastasis in 5 cases (10%), and 3 patients (6%) died of lung metastasis. T2b or more advanced T stage was associated with a risk of shorter overall survival (HR = 5.3, 95% CI = 1.2-23, p = 0.024) compared with T2a or earlier stage, as well as lymph node metastasis (HR = 82, 95% CI = 2.6-2.6e+03, p = 0.013). A positive surgical margin increased the risk of local recurrence (HR = 37, 95% CI = 5.9- 235, p = 0.00012).

conclusionProper diagnosis and margin-free resection are necessary before eyelid sebaceous carcinoma can further develop.

Indexed as

Adenocarcinoma, SebaceousEyelid NeoplasmsEyelidsSebaceous Gland NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansJapanMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesEyelidPrognosisPrognostic factorSebaceous carcinoma

Identifiers

PMID40413654
PMCPMC12339578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.